Skip to main content

Abdominal Pain

3
Pipeline Programs
6
Companies
6
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
1
1
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Pfizer
PfizerNEW YORK, NY
1 program
1
Pregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeksPhase 41 trial
Active Trials
NCT00310765Terminated18Est. Aug 2008
Human BioSciences
Human BioSciencesWV - Martinsburg
2 programs
1
1
Ketamine hydrochloridePhase 31 trial
Social Learning and Cognitive Behavioral TherapyPhase 21 trial
Active Trials
NCT00494260Completed200Est. Jun 2010
NCT06835504Not Yet Recruiting1,010Est. Feb 2030
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
AEGISN/A1 trial
Active Trials
NCT02436057Completed255Est. Dec 2015
CENTOGENE
CENTOGENEGermany - Rostock
1 program
Epidemiological Analysis for Hereditary Angioedema DiseaseN/A1 trial
Active Trials
NCT03558009Completed2,318Est. Apr 2022
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Hyoscine Butylbromide - TabletPHASE_31 trial
Active Trials
NCT02242305Completed302Est. Jul 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
PfizerPregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks
Human BioSciencesKetamine hydrochloride
Boehringer IngelheimHyoscine Butylbromide - Tablet
Human BioSciencesSocial Learning and Cognitive Behavioral Therapy
CENTOGENEEpidemiological Analysis for Hereditary Angioedema Disease
Angeles TherapeuticsAEGIS

Clinical Trials (6)

Total enrollment: 4,103 patients across 6 trials

NCT00310765PfizerPregabalin 75 or 150 mg BID for 7 weeks followed by open label pregabalin 150 mg BID for 4 weeks

Pregabalin for Abdominal Pain From Adhesions

Start: Mar 2006Est. completion: Aug 200818 patients
Phase 4Terminated
NCT06835504Human BioSciencesKetamine hydrochloride

Morphine or Ketamine for Analgesia

Start: Sep 2026Est. completion: Feb 20301,010 patients
Phase 3Not Yet Recruiting
NCT02242305Boehringer IngelheimHyoscine Butylbromide - Tablet

Study to Evaluate the Efficacy and Safety of Hyoscine Butylbromide Tablets for the Treatment of Occasional or Recurrent Episodes of Gastric or Intestinal Spasm-like Pain or Discomfort

Start: Nov 2008Est. completion: Jul 2009302 patients
Phase 3Completed
NCT00494260Human BioSciencesSocial Learning and Cognitive Behavioral Therapy

Managing Recurrent Abdominal Pain

Start: Nov 2003Est. completion: Jun 2010200 patients
Phase 2Completed
NCT03558009CENTOGENEEpidemiological Analysis for Hereditary Angioedema Disease

Epidemiological Analysis for Hereditary Angioedema Disease

Start: Sep 2018Est. completion: Apr 20222,318 patients
N/ACompleted
NCT02436057Angeles TherapeuticsAEGIS

Development and Validation of the Automated Evaluation of Gastrointestinal Symptoms (AEGIS) Platform

Start: Jul 2014Est. completion: Dec 2015255 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
6 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.